Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio)

重组人CTLA-4-Fc融合蛋白（北京伟德杰生物）

Report date: 2025/06/09 17:26:47

Base Information

Drug NameRecombinant human CTLA-4-FC fusion protein(Beijing Vdjbio)
Drug Alias NameRecombinant Humanized CTLA-4-FC Fusion Protein - Beijing Weidejie BiotechnologyVDJ002VDJ-002
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 80 modulatorsCluster of differentiation 86 modulators
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Vdjbio Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Vdjbio Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A